Kornimate/medical-research-clean huggingface dataset:
aminolaevulinic acid photodynamic therapy of cervical persistent hpv infection and cervical neoplasia

Conditions: Cervical Persistent High Risk HPV Infection; Cervical Intraepithelial Neoplasia

Summary: the study will examine the effect of aminolaevulinic acid (ala) photodynamic therapy (pdt) of cervical precancerous lesions in women.


Eligibility criteria:
inclusion criteria: 1. premenopausal women, 25-50 years of age 2. meet one of the 3 following conditions: high-risk hpv-dna persistently positive for at least 6 months, without cin or higher grade lesions as verified by cervical biopsy within the last 3 months; cin1 as verified by cervical biopsy within the last 3 months and high-risk hpv-dna positive; cin2/3 as verified by cervical biopsy within the last 3 months, with intense desire to retain the cervical structure or function 3. satisfactory colposcopy examination (visibility of entire transformation zone and entire lesion margin ) and endocervical curettage negative 4. in good health condition as confirmed by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis on the screening and baseline evaluation within the last 4 weeks of the onset of the study 5. meet the following conditions: pregnancy test negative; no pregnancy plan during the trial;no sexuality or reliable contraceptive measures taken since last menstruation to the onset of the study, agreeing to adopt reliable contraceptive measures during the study 6. written informed consent signed exclusion criteria: 1. atypical glandular cells of undetermined significance (agus) or adenocarcinoma in situ (ais) on cytology ,or malignant cells on cytology or histology, or other suspicion of either micro-invasive or invasive disease 2. invasive carcinoma possibility or positive endocervical curettage on colposcopy 3. severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological infection as per clinical examination 4. undiagnosed vaginal bleeding 5. with allergic disease at present; known or suspected porphyria; known allergy to ala or similar compounds 6. evidence or history of clinically significant cardiovascular, endocrine, neurologic, pulmonary, hematological, immunological, psychiatric, metabolic disease or other serious diseases 7. pregnancy or nursing 8. therapeutic drug or other therapeutic measures applied on cervix or rectum within the last 2 weeks of the onset of the study 9. participation in any clinical studies within the last 30 days 10. subjects that the investigators judged to be not suitable to participate the study besides above
the impact of vitamin d on tuberculosis among koreans

Conditions: Tuberculosis

Summary: vitamin d has been regarded to be beneficial to tuberculosis (tb) patients. the aim of this study is to elucidate the role of vitamin d deficiency in development and treatment outcomes among korean tb patients. furthermore, the impact of genotypes of vitamin d receptor gene on tb development will also be evaluated.


Eligibility criteria:
inclusion criteria: * older than 19 years * diagnosed and treated having a tuberculosis exclusion criteria: * positive hiv antibody
early prediction of placenta accreta by ultrasound and color doppler

Conditions: Placenta Accreta

Summary: placenta accreta is a substantially life threatening condition and one of the causes of maternal morbidity and mortality in the world. according to study done in united kingdom, the estimated incidence of placenta accreta/increta/percreta was 1.7 per 10,000 maternities overall and 577 per 10,000 in women with both a previous cesarean delivery and placenta previa. in a tertiary south italian center, the incidence increased from 0.12% during the 1970s, to 0.31% during the 2000s.while in united states of america, the prevalence of placenta accreta was 3.7 per 1000 deliveries.


Eligibility criteria:
inclusion criteria: 1. low implantation of the gestational sac (\<4 cm from external os) by transvaginal ultrasound 2. presence of placental lakes by transvaginal ultrasound 3. disruption of placental-myometrial interface by transvaginal ultrasound 4. trophoblast overlapping a uterine scar (cesarean section, myomectomy) by transvaginal ultrasound 5. intraplacental dilated vessels by doppler ultrasound 6. turbulent blood flows by doppler ultrasound 7. greatly increased periplacental vascularity by doppler ultrasound exclusion criteria: a) cases far away from our hospital and expected to be lost to be followed. b) pregnant women who will refuse to participate -
salt sensitivity hypertension and lens opacities

Conditions: Salt Hypertension From Excess Dietary Salt; Lens Opacities

Summary: salt-sensitive hypertension (ssh) accounts for about the half of all hypertension (ht) cases .in ssh, na+/k+-atpase activity is impaired. impaired na+/k+-atpase activity in the lens epithelium results in cortical opacities in the peripheral equator of the lens. this study analyzed 305 patients with hypertension aged between 40 and 80 years and 124 non-ht controls. a total of 163 patients with ht who were admitted to the emergency service at least once with a minimum increase of 10% in their systolic and diastolic blood pressure after consuming salted food met the eligible criteria for ht and were included in the ssh group. a total of 142 patients who were previously diagnosed with ht but had no previous history were considered non-ssh. two researchers examined the presence of cortical lens opacities biomicroscopically using the diffuse, direct, scheimpflug, and retroillumination from fundus methods.

the number of patients with hypertension (ht) worldwide is estimated to reach 1.56 billion by 2025.ht accounts for almost 50% of deaths due to stroke and coronary artery disease. salt-sensitive hypertension (ssh) accounts for about the half of all ht cases. na+ /k+-atpase activity is impaired in patients with ssh . impaired na+ /k+-atpase activity in the lens epithelium results in cortical opacities in the peripheral equatorial region of the lens.a definite diagnosis of salt sensitivity is difficult, expensive, and associated with low patient compliance. salt sensitivity is a risk factor for cardiovascular mortality and morbidity regardless of blood pressure and for other diseases such as asthma, gastric carcinoma, osteoporosis, and renal dysfunction. the present study is the first to investigate the potential of using lens opacity to predict ssh. the transparency of the whole lens is largely based on epithelial cell permeability and na+ /k+-atpase activity. circulation is activated by na+ /k+-atpases, which are present at 20-fold normal concentrations, particularly in the equatorial than in the anterior epithelial cells. the mechanisms associated with ssh pathogenesis, such as signaling pathways involving src family kinase (sfk), endothelin, connexin, brain natriuretic peptide (bnp), aldosterone, transient receptor protein v4 (trpv4) ion channel, with-no-lysine kinase-ste20-like proline/alanine rich kinase/oxidative stress-responsive kinase 1 (wnk-spak/osr1), and ras-related c3 botulinum toxin substrate (rac1) , are important to the physiology of the lens epithelium. compelling studies suggest that inhibition of these pathways may facilitate opacity.

Eligibility criteria:
inclusion criteria: salt sensitivity hypertension patients non-ssh, salt-resistant ht (srh) patients control patients without ht, aged 40-80 years. exclusion criteria: cataracts diabetes mellitus smoking hypo/hypercalcemia hyperparathyroidism eye trauma coronary artery disease cardiac failure renal failure -
china action on spine and hip status

Conditions: Osteoporosis; Liver Steatosis; Metabolic Syndrome; Obesity

Summary: 1. to determine the prevalences of osteoporotic fracture in elderly chinese population. 2. to determine the prevalences of osteoporosis in elderly chinese population using qct bmd measurement. 3. to investigate the difference in the prevalences of osteoporosis between cities and urban-rural area in china. 4. to investigate the association of body composition with osteoporosis 5. to investigate the prevalence of liver steatosis in china 6. to investigate the application of qct fat measurement

osteoporosis and osteoarthritis (oa) both are very common in elderly population,it is particular important for china with a huge aging population in the coming years.bone mineral density measured by quantitative computed tomography (qct) or dual energy x-ray absorptiometry (dxa) is the surrogate for bone health status and diagnosis of osteoporosis and oa. in this study we utilize the large-scale population based epidemiology study (pure) population,spine and hip qct and/or dxa will be obtained for the subject to investigate the prevalence of osteoporosis and osteoarthritis in elderly chinese population. we also study the relation between bone mineral density with osteoporotic fracture and oa more than 3000 subjects selected from the pure study participants in beijing and other centers in china will be recruited to this study. more precisely, the subjects are consisted of the females over 55 years and males over 60 years old, along with the 20% randomly selected pure participants for blood sampling. beijing ji shui tan hospital will be the coordinate center for the whole study, beijing shi jing shan hospital, beijing shun yi traditional medicine hospital and taiyuan central hospital of shanxi will participate, other centers may be added late. bone mineral density of spine and hip will be measured with qct and/or dxa. quantitative computed tomography qct pro (mindways software, inc. usa) will be used for all qct measurement, the ct scanner will be the clinical ct scanner of the local participated center. quality control and monitoring will be conducted by beijing ji shui tan hospital, as well as the centralised image interpretation. therefore, this study is designed to provide the current and reliable prevalence of osteoporotic fracture, osteoporosis, oa in elderly chinese population using qct and/or dxa. the performance of qct and dxa in the diagnosis of osteoporosis , as well as the association of body composition with osteoporosis will be assessed.

Eligibility criteria:
1. inclusion criteria: 1. participants of the pure study in china (pure china study) 2. be willing to and be able to join in the study and signed informed consent 2. exclusion criteria: 1. pregnant 2. spine and both hip implants

Keywords: osteoporosis osteoarthritis bone mineral density computed xray tomography liver steatosis obesity
should any one airway clearance technique be recommended for people with cystic fibrosis?

Conditions: Cystic Fibrosis

Summary: the study was to evaluate the long term effects, over one year, of five airway clearance techniques used by people with cystic fibrosis (active cycle of breathing techniques, autogenic drainage, positive expiratory pressure and oscillating positive expiratory pressure (r-c cornet and flutter)). the primary outcome measure was forced expiratory volume in one second (fev1)and the null hypothesis was that there are no differences among the regimens.


Eligibility criteria:
inclusion criteria: * diagnosis of cystic fibrosis (genotype or sweat sodium concentration greater than 70 mmol/litre) * forced expiratory volume in one second greater than or equal to 25% predicted, on assessment for entry to the study. exclusion criteria: * evidence of a current respiratory exacerbation (thornton et al 2004) * current severe haemoptysis * past history of pneumothorax * awaiting lung / heart-lung transplantation * pregnancy * recent (within 3 months) acquisition of burkholderia cepacia

Keywords: cystic fibrosis airway clearance
a study to evaluate the effects of ym872 on stroke lesion volume in acute stroke patients

Conditions: Cerebrovascular Accident

Summary: this study will investigate the effects of a potential neuroprotectant compound, ym872, in the treatment of acute ischemic stroke. the study will determine if a 24-hour infusion of ym872, given within 6 hours of stroke onset, reduces the ischemic lesion volume as measured by mri at 28 days after the infusion is given. the clinical effects of ym872 will also be determined by neurological function and disability scores at follow up visits through day 90 of the study.


Eligibility criteria:
inclusion criteria: * patients who have suffered an acute ischemic stroke and can be evaluated and treatment initiated within 6 hours after the onset of symptoms (onset is defined as the time that which the patient was last seen in a normal state, or bedtime for unwitnessed strokes occurring during the night). * patients who have a three dimensionally measurable lesion compatible with an acute ischemic stroke measured using mri. * patients who have a national institutes of health stroke scale (nihss) score of at least 7 but not more than 23 and who are conscious. * patients who are able to provide written informed consent or have consent provided by a legally authorized representative. * patients who are at least 18 years of age. * other criteria as specified in the study protocol exclusion criteria: * patients who have received alteplase (t-pa) for the current stroke episode. it is assumed that all patients who are eligible will receive treatment with t-pa. * patients who have disability and functional limitations prior to the current stroke episode (e.g. deficit resulting from a prior stroke). * patients who have brain hemorrhage. * patients who have stroke of the brainstem or cerebellum. * patients who cannot be evaluated using mri due to the presence of a pacemaker, claustrophobia, need for sedation, etc. * patients who have renal (kidney) disease or insufficiency. * patients who have active epilepsy or convulsions during the current stroke episode. * patients who are iv drug users or are inebriated. * patients who have a history of drug-related anaphylaxis. * patients who have taken sedatives, anticonvulsants, or any medication with sedating effects in the 10 days prior study enrollment. * patients who have taken more than 1.3 g of aspirin per day in the 2 days prior to enrollment. * patients who have a known vitamin hypersensitivity. * other exclusion criteria as specified by the study protocol.

Keywords: artist acute ischemic stroke
efficacy of oral ab1010 in adult patients with severe persistent corticosteroid dependent asthma

Conditions: Asthma

Summary: the aim of the study is to evaluate, comparatively to a placebo, the activity of oral ab1010, administered at three dose levels during 4 months to patients with severe persistent corticosteroid dependent asthma, assessed on : * the decrease in corticosteroid therapy * the asthma control improvement (symptomatic scores, rescue medication intake, respiratory function) * the pharmacokinetic profile of ab1010 * clinical and biological safety parameters

this is a double-blind, placebo-controlled, randomized, parallel-groups, multicenter study of daily oral ab1010 at doses 3, 4.5 and 6 mg/kg/day. the study treatment is administered for 16 weeks: * the first 4 weeks are a run-in period during which corticosteroids remain stable; * during the following 8 weeks, corticosteroids are decreased every week until weaning or an exacerbation occurs; * the last 4 weeks are a stabilization period. patients have to perform a visit every 2 weeks during run-in, then every week for the following 3 months.

Eligibility criteria:
inclusion criteria: * known severe persistent corticosteroid dependent asthma (who/nhlbi workshop definition). * disease duration \> 1 year. * stable disease with no exacerbation episode for at least one month before inclusion. * daily treated with 10 to 50 mg of equivalent prednisolone, with stable dosage since at least 3 months. * known reversibility of bronchial obstruction, defined as an enhancement of fev1 ≥ 12%, 10 minutes after salbutamol administration, or 14 days after systemic treatment with 1 mg/kg/day of equivalent prednisolone. exclusion criteria: * asthmatic patients still exposed to allergens or to triggering factors influencing asthma control. * history of infection requiring hospitalization or treatment with antibiotics within 2 weeks of screening.

Keywords: severe asthma corticosteroids dependent asthma exacerbation weaning tyrosine kinase inhibitor severe persistent corticosteroid dependent asthma
wal 801 cl dry syrup in pediatric atopic dermatitis patients

Conditions: Dermatitis, Atopic

Summary: the safety and efficacy of wal 801 cl (epinastine hydrochloride) dry syrup in the treatment of atopic dermatitis in children was evaluated and plasma drug concentrations were measured.


Eligibility criteria:
inclusion criteria: for inclusion in this study, subjects must be pediatric atopic dermatitis patients that meet the following criteria and thus be appropriate for observation of pruritus. diagnosis of atopic dermatitis will be conducted in accordance with the "definition and diagnostic criteria of atopic dermatitis", issued by the japanese dermatological association. * 15 years of age or younger * body weight of 14 kg or more * outpatients * the patient has been undergoing treatment with a "very strong" or lower-grade external steroid preparation for \>= 1 week at the time informed consent is obtained * pruritus with "2" or higher grade at the start time of administration exclusion criteria: * use of sustained release adrenocorticotropic hormone (kenacort® a, depo-medrol®, etc.), oral preparation of methotrexate, or oral preparation of ciclosporin, within 4 weeks before initial administration of the investigational product * oral intake, inhalation and injection of any steroid within 2 weeks before initial administration of the investigational product * use of any external steroid preparation at "strongest" in any sites other than the face or scalp within 2 weeks before initial administration of the investigational product * undergoing phototherapy * undergoing specific desensitization therapy or modulation therapy * past history of contact dermatitis caused by external steroid preparation * possibility of exacerbation by an external steroid preparation of infectious skin disease caused by bacteria, fungi, or virus * clinically significant hepatic, renal, or cardiac disease or other complications: therefore, judgement that the patient was ineligible for inclusion in this study. patients must be excluded from the study if the patients fell under grade 2 or more, in the mhw (ministry of health and welfare) adverse reaction severity classification criteria * past history of allergy to any drug * participation in any other clinical study, or history of participation in any other clinical study within 6 months before the date when the patient gave consent to participate in this study * judgement by the principal investigator or investigator that the patient is ineligible for inclusion in this study
interest of real time measurement of autonomous nervous system for the detection of brain death

Conditions: Cerebral Hematoma, Traumatic; Intracerebral Hemorrhage, Traumatic; Traumatic Brain Hemorrhage; Traumatic Brain Injury

Summary: context: a major lack of organ donors is a serious public health problem. it determines a prolonged delay before a transplant can be performed and thus a significant number of deaths of patients waiting for transplantation. the aim of this project is to reduce the delay of the diagnosis of brain death, and also to improve its diagnosis in the intensive care unit. the diagnosis of brain death is strictly defined by the law and relies either on two consecutive flat electroencephalograms recorded at an interval of four hours, or on the lack of cerebral circulation during a brain angiography performed after suspecting brain death on the clinical exam. however, in usual practice, it is difficult to have all the needed clinical arguments, and their interpretation can be difficult in the pathological context. this may participate in the delay and the lack of patients potentially donors. pre-study: in a pilot study, fifty subjects with severe cerebral lesions, had a continuous ecg recording. the investigators could find that a decrease in autonomic nervous system activity, as measured through the ecg, was correlated to the transition to brain death assessed by cerebral angiography. the loss of cardiac variability was always observed between two cerebral angiographies, one before and the second after brain death. this study allowed the investigators to calculate the threshold values of sympathetic and parasympathetic activities to confirm brain death.

aim: the aim of this second study is to validate prospectively the interest of the analysis in real-time of autonomic nervous system activity to detect brain death. benefits expected: increase the number of organ donors and the number of organs removal available for transplantation.

Eligibility criteria:
inclusion criteria: * severe cerebral lesions * admitted in intensive care units exclusion criteria: * neoplastic pathology * prior myocardiac infarction * hearth failure * atrial fibrillation * insulin-treated diabetes mellitus * cardiac pacemaker

Keywords: autonomous nervous system brain death organs transplantation
angiotensin ii pathway and postoperative hypoxemia

Conditions: Aortic Dissection

Summary: acute type a aortic dissection is often accompanied by postoperative hypoxemia, the cause of which is not fully understood. angiotensin ii is an important component of the renin-angiotensin system (ras), which has been suggested to be involved in the development of aortic dissection and pulmonary inflammation.the purpose of this study was to investigate the role and mechanism of angiotensin ii pathway in postoperative hypoxemia after acute type a aortic dissection, and to provide reference for clinical application


Eligibility criteria:
inclusion criteria: * patients undergoing surgery for acute type a aortic dissection * age between 18 to 80 exclusion criteria: * perioperative severe cardiac insufficiency * rejection of consent